FeesSafety
Pluang+
icon
Up to 4x
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Eli Lilly And Co (LLY) Stock Price Today

24H
1W
1M
3M
YTD
1Y
5Y

NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...

Market News
52 minutes ago
Na
Neutral
NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

South Korean stocks plunge over 8% on Friday amid tech turmoil and AI regulation fears

South Korea's Kospi index dropped more than 8% on Friday, reflecting global tech sector instability and concerns about stricter AI regulations under Democratic governments. This sharp decline signals heightened market volatility and investor caution,...

Market News
5 hours ago
Barrons
Bearish
news icon
South Korean stocks plunge over 8% on Friday amid tech turmoil and AI regulation fears

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
5 hours ago
Cullinan Therapeutics, Inc.
Bullish
news icon
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

AVITA Medical to host investor webinar on Nov 11 covering Q3 2026 results and business update

AVITA Medical announced an investor webinar on November 11, 2026, where CEO Cary Vance and CFO David O’Toole will discuss the company's third-quarter 2026 financial and business results. The session will include a Q&A segment for participants who can...

Market News
5 hours ago
GlobeNewsWire
Neutral
AVITA Medical to host investor webinar on Nov 11 covering Q3 2026 results and business update

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
5 hours ago
Crispr Therapeutics
Bullish
news icon
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

Reinvesting dividends turned $1,000 in Procter & Gamble into $4,656 over 20 years.

Investing $1,000 in Procter & Gamble (P&G) in 2006 and reinvesting all dividends grew the investment to $4,656 by 2026. P&G's steady demand for everyday products supports 70 consecutive years of dividend increases, with dividends rising from $0.31 to...

Market News
5 hours ago
24/7 Wall Street
Bullish
news icon
Reinvesting dividends turned $1,000 in Procter & Gamble into $4,656 over 20 years.

3 stocks with recurring revenue face challenges but offer long-term growth potential.

Three companies—Otis Worldwide, Rollins, and Republic Services—offer recurring revenue through essential services like elevator maintenance, pest control, and waste management. Despite their steady cash flows and customer loyalty, Otis and Rollins fa...

Market News
5 hours ago
24/7 Wall Street
Neutral
3 stocks with recurring revenue face challenges but offer long-term growth potential.

Lawsuit probes J.B. Hunt for allegedly misleading investors after Q3 earnings warning

Rosen Law Firm is investigating J.B. Hunt Transport Services for possibly providing misleading business information to investors after the company warned of a Q3 earnings decline. The firm's shares dropped sharply following a CNBC report about increa...

Market News
5 hours ago
PRNewsWire
Bearish
news icon
Lawsuit probes J.B. Hunt for allegedly misleading investors after Q3 earnings warning

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
5 hours ago
Cabaletta Bio, Inc.
Bullish
news icon
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cisco's 2000 peak stock price took over 25 years to surpass, highlighting risks for today's AI investors.

Cisco briefly became the world's most valuable company in March 2000, with its stock closing at $80.06. However, investors who bought at that peak had to wait over 25 years to see a higher closing price, as the dot-com crash caused an 87% drop in sha...

Market News
5 hours ago
24/7 Wall Street
Bullish
news icon
Cisco's 2000 peak stock price took over 25 years to surpass, highlighting risks for today's AI investors.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

Key Stats

  • Market Cap
    $1.21T
  • Volume
    3,579,407
  • Sector
    Health
  • 52W High
    $1.42K
  • 52W Low
    $851.21
  • Typical Hold Time
    94 Days
  • Enterprise Value
    $1.25T
  • Div Yield
    0.51%
  • Trading Activity
    -
$1,354
52W Low: $851.21
29 Apr 2026
52W High: $1,417.72
04 Nov 2026

Track Eli Lilly And Co (LLY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Eli Lilly And Co has traded between a low of $851.21 and a high of $1,417.72, highlighting its annual price range. Buy and sell Eli Lilly And Co shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!